Laboratory Testing for Prescription Opioids

Journal of Medical Toxicology

Volumn 8, Issue 4, 2012, Pages 408-416

  Milone, Michael C ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Opioids; Pain medicine; Screening; Substance abuse

Indexed keywords

BUPRENORPHINE; CODEINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT; OXYCODONE; OXYMORPHONE;

ARTICLE; DRUG DETERMINATION; DRUG METABOLISM; DRUG MISUSE; DRUG STRUCTURE; DRUG URINE LEVEL; HUMAN; LABORATORY TEST; PRESCRIPTION; SCREENING TEST; URINALYSIS;

EID: 84870701549     PISSN: 15569039     EISSN: 19376995     Source Type: Journal    
DOI: 10.1007/s13181-012-0274-7     Document Type: Article

References (99)

1. Stang P, Von Korff M, Galer BS (1998) Reduced labor force participation among primary care patients with headache. J Gen Intern Med 13(5): 296-302, Epub 1998/06/05.
2. Volkow ND, McLellan TA, Cotto JH, Karithanom M, Weiss SR (2011) Characteristics of opioid prescriptions in 2009. JAMA: J Am Med Assoc 305(13): 1299-1301, Epub 2011/04/07.
3. Manchikanti L, Helm Ii S, Fellows B, Janata JW, Pampati V, Grider JS et al (2012) Opioid epidemic in the United States. Pain Physician 15(3 Suppl), ES9- ES38. Epub 2012/07/20.
4. Okie S (2010) A flood of opioids, a rising tide of deaths. N Engl J Med 363(21): 1981-1985, Epub 2010/11/19.
5. Akbik H, Butler SF, Budman SH, Fernandez K, Katz NP, Jamison RN (2006) Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). J Pain Symptom Manag 32(3): 287-293, Epub 2006/08/31.
6. Butler SF, Budman SH, Fernandez K, Jamison RN (2004) Validation of a screener and opioid assessment measure for patients with chronic pain. Pain 112(1-2): 65-75, Epub 2004/10/21.
7. Webster LR, Webster RM (2005) Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med 6(6): 432-442, Epub 2005/12/13.
8. Yudko E, Lozhkina O, Fouts A (2007) A comprehensive review of the psychometric properties of the drug abuse screening test. J Subst Abus Treat 32(2): 189-198, Epub 2007/02/20.
9. Butler SF, Budman SH, Fernandez KC, Houle B, Benoit C, Katz N et al (2007) Development and validation of the current opioid misuse measure. Pain 130(1-2): 144-156, Epub 2007/05/12.
10. Gugelmann HM, Perrone J (2011) Can prescription drug monitoring programs help limit opioid abuse. JAMA: J Am Med Assoc 306(20): 2258-2259, Epub 2011/11/24.
11. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P et al (2009) Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain: Off J Am Pain Soc 10(2): 113-130. doi: 113, Epub 2009/02/04.
12. Notice changing the opiate testing cutoff concentrations (1998) Federal Register: United States Department of Health and Human Services p. 29916.
13. Clinical and Laboratory Standards Institute (2005) Clinical and Laboratory Standards Institute: Toxicology and Drug Testing in the Clinical Laboratory; Approved Guideline, 2nd edn. Clinical and Laboratory Standards Institute, Wayne, pp 1-51.
14. Anglin D, Westland CA (1989) Drug monitoring in the workplace: Results from the California commercial laboratory drug testing project. 1989.
15. Heltsley R, Zichterman A, Black DL, Cawthon B, Robert T, Moser F et al (2010) Urine drug testing of chronic pain patients. II. Prevalence patterns of prescription opiates and metabolites. J Anal Toxicol 34(1): 32-38, Epub 2010/01/30.
16. Reisfield GM, Salazar E, Bertholf RL (2007) Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci 37(4): 301-314, Epub 2007/11/15.
17. Luzzi VI, Saunders AN, Koenig JW, Turk J, Lo SF, Garg UC et al (2004) Analytic performance of immunoassays for drugs of abuse below established cutoff values. Clin Chem 50(4): 717-722, Epub 2004/02/07.
18. Pesce A, West C, West R, Crews B, Mikel C, Rosenthal M et al (2011) Determination of medication cutoff values in a pain patient population. J Opioid Manag 7(2): 117-122, Epub 2011/05/13.
19. Baden LR, Horowitz G, Jacoby H, Eliopoulos GM (2001) Quinolones and falsepositive urine screening for opiates by immunoassay technology. JAMA: J Am Med Assoc 286(24): 3115-3119, Epub 2002/01/05.
20. Smith ML, Shimomura ET, Summers J, Paul BD, Nichols D, Shippee R et al (2000) Detection times and analytical performance of commercial urine opiate immunoassays following heroin administration. J Anal Toxicol 24(7): 522-529, Epub 2000/10/24.
21. Cook JD (2011) Minutes from the SAMHSA center for substance abuse prevention drug testing advisory board meeting, July 12-13. In: SAMHSA, editor. Accessed August 20, 20122011.
22. Levine B (2010)Principles of forensic toxicology. 3rd ed. Washington, DC: American Association for Clinical Chemistry; viii, 471 p. p.
23. Smith ML, Hughes RO, Levine B, Dickerson S, Darwin WD, Cone EJ (1995) Forensic drug testing for opiates. VI. Urine testing for hydromorphone, hydrocodone, oxymorphone, and oxycodone with commercial opiate immunoassays and gas chromatography-mass spectrometry. J Anal Toxicol 19(1): 18-26, Epub 1995/01/01.
24. Levy S, Sherritt L, Vaughan BL, Germak M, Knight JR (2007) Results of random drug testing in an adolescent substance abuse program. Pediatrics 119(4): e843-e848, Epub 2007/04/04.
25. Melanson SE, Baskin L, Magnani B, Kwong TC, Dizon A, Wu AH (2010) Interpretation and utility of drug of abuse immunoassays: lessons from laboratory drug testing surveys. Arch Pathol Lab Med 134(5): 735-739, Epub 2010/05/06.
26. Gingras M, Laberge MH, Lefebvre M (2010) Evaluation of the usefulness of an oxycodone immunoassay in combination with a traditional opiate immunoassay for the screening of opiates in urine. J Anal Toxicol 34(2): 78-83, Epub 2010/03/13.
27. Wang G, Huynh K, Barhate R, Rodrigues W, Moore C, Coulter C et al (2011) Development of a homogeneous immunoassay for the detection of fentanyl in urine. Forensic Sci Int 206(1-3): 127-131, Epub 2010/08/31.
28. Melanson SE, Snyder ML, Jarolim P, Flood JG (2012) A new highly specific buprenorphine immunoassay for monitoring buprenorphine compliance and abuse. J Anal Toxicol 36(3): 201-206, Epub 2012/03/16.
29. Leino A, Loo BM (2007) Comparison of three commercial tests for buprenorphine screening in urine. Ann Clin Biochem 44(Pt 6): 563-565, Epub 2007/10/27.
30. Bottcher M, Beck O (2005) Evaluation of buprenorphine CEDIA assay versus GC-MS and ELISA using urine samples from patients in substitution treatment. J Anal Toxicol 29(8): 769-776, Epub 2005/12/17.
31. Kronstrand R, Selden TG, Josefsson M (2003) Analysis of buprenorphine, norbuprenorphine, and their glucuronides in urine by liquid chromatographymass spectrometry. J Anal Toxicol 27(7): 464-470, Epub 2003/11/11.
32. Cooreman S, Deprez C, Martens F, van Bocxlaer J, Croes K (2010) A comprehensive LC-MS-based quantitative analysis of fentanyl-like drugs in plasma and urine. J Sep Sci 33(17-18): 2654-2662, Epub 2010/07/27.
33. Huynh NH, Tyrefors N, Ekman L, Johansson M (2005) Determination of fentanyl in human plasma and fentanyl and norfentanyl in human urine using LC-MS/MS. J Pharm Biomed Anal 37(5): 1095-1100, Epub 2005/05/03.
34. Starrels JL, Fox AD, Kunins HV, Cunningham CO (2012) They don't know what they don't know: internal medicine residents' knowledge and confidence in urine drug test interpretation for patients with chronic pain. J Gen Intern Med. Epub 2012/07/21.
35. Levy S, Harris SK, Sherritt L, Angulo M, Knight JR (2006) Drug testing of adolescents in ambulatory medicine: physician practices and knowledge. Arch Pediatr Adolesc Med 160(2): 146-150, Epub 2006/02/08.
36. Smith HS (2009) Opioid metabolism. Mayo Clin Proc 84(7): 613-624, Epub 2009/07/02.
37. Cone EJ, Caplan YH, Moser F, Robert T, Black D (2008) Evidence that morphine is metabolized to hydromorphone but not to oxymorphone. J Anal Toxicol 32(4): 319-323, Epub 2008/04/24.
38. Reisfield GM, Chronister CW, Goldberger BA, Bertholf RL (2009) Unexpected urine drug testing results in a hospice patient on high-dose morphine therapy. Clin Chem 55(10): 1765-1768, Epub 2009/09/30.
39. Wasan AD, Michna E, Janfaza D, Greenfield S, Teter CJ, Jamison RN (2008) Interpreting urine drug tests: prevalence of morphine metabolism to hydromorphone in chronic pain patients treated with morphine. Pain Med 9(7): 918-923, Epub 2008/07/12.
40. Smith ML, Shimomura ET, Summers J, Paul BD, Jenkins AJ, Darwin WD et al (2001) Urinary excretion profiles for total morphine, free morphine, and 6- acetylmorphine following smoked and intravenous heroin. J Anal Toxicol 25(7): 504-514, Epub 2001/10/16.
41. Pelders MG, Ros JJ (1996) Poppy seeds: differences in morphine and codeine content and variation in inter- and intra-individual excretion. J Forensic Sci 41(2): 209-212, Epub 1996/03/01.
42. Selavka CM (1991) Poppy seed ingestion as a contributing factor to opiatepositive urinalysis results: the Pacific perspective. J Forensic Sci 36(3): 685-696, Epub 1991/05/01.
43. Ceder G, Jones AW (2001) Concentration ratios of morphine to codeine in blood of impaired drivers as evidence of heroin use and not medication with codeine. Clin Chem 47(11): 1980-1984, Epub 2001/10/24.
44. Moriya F, Chan KM, Hashimoto Y (1999) Concentrations of morphine and codeine in urine of heroin abusers. Leg Med (Tokyo) 1(3): 140-144, Epub 2003/08/26.
45. Jones AW, Holmgren A, Kugelberg FC (2008) Driving under the influence of opiates: concentration relationships between morphine, codeine, 6-acetyl morphine, and ethyl morphine in blood. J Anal Toxicol 32(4): 265-272, Epub 2008/04/24.
46. Konstantinova SV, Normann PT, Arnestad M, Karinen R, Christophersen AS, Morland J (2012) Morphine to codeine concentration ratio in blood and urine as a marker of illicit heroin use in forensic autopsy samples. Forensic Sci Int 217(1-3): 216-221, Epub 2011/12/06.
47. Lotsch J (2005) Opioid metabolites. J Pain Symptom Manag 29(5 Suppl): S10-S24, Epub 2005/05/24.
48. Desmeules J, Gascon MP, Dayer P, Magistris M (1991) Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 41(1): 23-26, Epub 1991/01/01.
49. Oyler JM, Cone EJ, Joseph RE Jr, Huestis MA (2000) Identification of hydrocodone in human urine following controlled codeine administration. J Anal Toxicol 24(7): 530-535, Epub 2000/10/24.
50. West R, Crews B, Mikel C, Almazan P, Latyshev S, Pesce A et al (2009) Anomalous observations of codeine in patients on morphine. Ther Drug Monit 31(6): 776-778, Epub 2009/11/26.
51. Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA (2004) CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol 57(3): 287-297, Epub 2004/03/05.
52. Valtier S, Bebarta VS (2012) Excretion profile of hydrocodone, hydromorphone and norhydrocodone in urine following single dose administration of hydrocodone to healthy volunteers. J Anal Toxicol. Epub 2012/07/12.
53. Barakat NH, Atayee RS, Best BM, Pesce AJ (2012) Relationship between the concentration of hydrocodone and its conversion to hydromorphone in chronic pain patients using urinary excretion data. J Anal Toxicol 36(4): 257-264, Epub 2012/04/19.
54. Jenkins AJ, Lavins ES, Hunek C (2009) Prevalence of dihydrocodeine in hydrocodone positive postmortem specimens. J Forensic Psychiatr 16(2): 64-66, Epub 2009/01/13.
55. Cone EJ, Zichterman A, Heltsley R, Black DL, Cawthon B, Robert T et al (2010) Urine testing for norcodeine, norhydrocodone, and noroxycodone facilitates interpretation and reduces false negatives. Forensic Sci Int 198(1-3): 58-61, Epub 2009/12/29.
56. Gimbel JS (2008) Oxymorphone: a mature molecule with new life. Drugs Today (Barc) 44(10): 767-782, Epub 2009/01/13.
57. Backer RC, Monforte JR, Poklis A (2005) Evaluation of the DRI oxycodone immunoassay for the detection of oxycodone in urine. J Anal Toxicol 29(7): 675-677, Epub 2006/01/20.
58. Poklis A (1995) Fentanyl: a review for clinical and analytical toxicologists. J Toxicol Clin Toxicol 33(5): 439-447, Epub 1995/01/01.
59. Krinsky CS, Lathrop SL, Crossey M, Baker G, Zumwalt R (2011) A toxicologybased review of fentanyl-related deaths in New Mexico (1986-2007). The Am J Forensic Med Pathol 32(4): 347-351, Epub 2011/10/12.
60. Mrvos R, Feuchter AC, Katz KD, Duback-Morris LF, Brooks DE, Krenzelok EP (2012) Whole fentanyl patch ingestion: a multi-center case series. Can J Emerg Med 42(5): 549-552, Epub 2011/06/21.
61. Poklis A, Backer R (2004) Urine concentrations of fentanyl and norfentanyl during application of Duragesic transdermal patches. J Anal Toxicol 28(6): 422-425, Epub 2004/11/02.
62. Mao CL, Zientek KD, Colahan PT, Kuo MY, Liu CH, Lee KM et al (2006) Development of an enzyme-linked immunosorbent assay for fentanyl and applications of fentanyl antibody-coated nanoparticles for sample preparation. J Pharm Biomed Anal 41(4): 1332-1341, Epub 2006/04/20.
63. Gillespie TJ, Gandolfi AJ, Maiorino RM, Vaughan RW (1981) Gas chromatographic determination of fentanyl and its analogues in human plasma. J Anal Toxicol 5(3): 133-137, Epub 1981/05/01.
64. Bentley JB, Borel JD, Nenad RE Jr, Gillespie TJ (1982) Age and fentanyl pharmacokinetics. Anesth Analg 61(12): 968-971, Epub 1982/12/01.
65. van Rooy HH, Vermeulen MP, Bovill JG (1981) The assay of fentanyl and its metabolites in plasma of patients using gas chromatography with alkali flame ionisation detection and gas chromatography-mass spectrometry. J Chromatogr 223(1): 85-93, Epub 1981/04/10.
66. Strano-Rossi S, Alvarez I, Tabernero MJ, Cabarcos P, Fernandez P, Bermejo AM (2011) Determination of fentanyl, metabolite and analogs in urine by GC/MS. J Appl Toxicol: JAT 31(7): 649-654, Epub 2010/12/07.
67. Coopman V, Cordonnier J, Pien K, van Varenbergh D (2007) LC-MS/MS analysis of fentanyl and norfentanyl in a fatality due to application of multiple Durogesic transdermal therapeutic systems. Forensic Sci Int 169(2-3): 223-227, Epub 2006/05/03.
68. Peer CJ, Shakleya DM, Younis IR, Kraner JC, Callery PS (2007) Direct-injection mass spectrometric method for the rapid identification of fentanyl and norfentanyl in postmortem urine of six drug-overdose cases. J Anal Toxicol 31(8): 515-521, Epub 2007/11/09.
69. Bagheri H, Es-haghi A, Khalilian F, Rouini MR (2007) Determination of fentanyl in human plasma by head-space solid-phase microextraction and gas chromatography-mass spectrometry. J Pharm Biomed Anal 43(5): 1763-1768, Epub 2007/01/26.
70. Thevis M, Geyer H, Bahr D, Schanzer W (2005) Identification of fentanyl, alfentanil, sufentanil, remifentanil and their major metabolites in human urine by liquid chromatography/tandem mass spectrometry for doping control purposes. Eur J Mass Spectrom (Chichester, Eng) 11(4): 419-427, Epub 2005/10/06.
71. Tetrault JM, Fiellin DA (2012) Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals. Drugs 72(2): 217-228, Epub 2012/01/13.
72. Martin CM (2011) Methadone: marvelous, malevolent, or merely misunderstood. Consult Pharm: J Am Soc Consult Pharmacists 26(1): 32-40, Epub 2011/01/13.
73. Collins AA, Merritt AP, Bourland JA (2012) Cross-reactivity of tapentadol specimens with DRI Methadone Enzyme Immunoassay. J Anal Toxicol. Epub 2012/08/11.
74. Davis MP (2012) Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol. Epub 2012/07/20.
75. Gopal S, Tzeng TB, Cowan A (2001) Development and validation of a sensitive analytical method for the simultaneous determination of buprenorphine and norbuprenorphine in human plasma. Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV 51(2): 147-151, Epub 2001/02/28.
76. George S, George C, Chauhan M (2004) The development and application of a rapid gas chromatography-mass spectrometry method to monitor buprenorphine withdrawal protocols. Forensic Sci Int 143(2-3): 121-125, Epub 2004/07/09.
77. Fuller DC (2008) A simple gas chromatography-mass spectrometry procedure for the simultaneous determination of buprenorphine and norbuprenorphine in human urine. J Anal Toxicol 32(8): 626-630, Epub 2008/11/15.
78. Hull MJ, Bierer MF, Griggs DA, Long WH, Nixon AL, Flood JG (2008) Urinary buprenorphine concentrations in patients treated with suboxone as determined by liquid chromatography-mass spectrometry and CEDIA immunoassay. J Anal Toxicol 32(7): 516-521, Epub 2008/08/21.
79. Twigger S, Fox E, Allen K (2008) Measurement of buprenorphine in urine: immunoassay versus LC-MS/MS. Ann Clin Biochem 45(Pt 3): 339, Epub 2008/05/17.
80. Hegstad S, Khiabani HZ, Oiestad EL, Berg T, Christophersen AS (2007) Rapid quantification of buprenorphine-glucuronide and norbuprenorphine-glucuronide in human urine by LC-MS-MS. J Anal Toxicol 31(4): 214-219, Epub 2007/06/09.
81. Rodriguez-Rosas ME, Lofwall MR, Strain EC, Siluk D, Wainer IW (2007) Simultaneous determination of buprenorphine, norbuprenorphine and the enantiomers of methadone and its metabolite (EDDP) in human plasma by liquid chromatography/mass spectrometry. J Chromatogr B, Anal Technol Biomed Life Sci 850(1-2): 538-543, Epub 2006/12/05.
82. McMillin GA, Davis R, Carlisle H, Clark C, Marin SJ, Moody DE (2012) Patterns of free (unconjugated) buprenorphine, norbuprenorphine, and their glucuronides in urine using liquid chromatography-tandem mass spectrometry. J Anal Toxicol 36(2): 81-87, Epub 2012/02/18.
83. Sutheimer CA, Cody JT (2009) Subversion of Regulated Workplace Drug Testing - Specimen Adulteration and Substitution. In: Ropero-Miller JD, Goldberger BA, Liu RH (eds) Handbook of workplace drug testing, 2nd edn. American Association for Clinical Chemistry, Washington, DC, pp 121-155.
84. Jenkins AJ, Oyler JM, Cone EJ (1995) Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. J Anal Toxicol 19(6): 359-374, Epub 1995/10/01.
85. Bosker WM, Huestic MA (2009) Oral fluid testing for drugs of abuse. Clinical chemistry 55(11): 1910-1931, Epub 2009/09/12.
86. Cone EJ, Clarke J, Tsanaclis L (2007) Prevalence and disposition of drugs of abuse and opioid treatment drugs in oral fluid. J Anal Toxicol 31(8): 424-433, Epub 2007/11/09.
87. Presley L, Lehrer M, Seiter W, Hahn D, Rowland B, Smith M et al (2003) High prevalence of 6-acetylmorphine in morphine-positive oral fluid specimens. Forensic Sci Int 133(1-2): 22-25, Epub 2003/05/14.
88. Crouch DJ, Walsh JM, Flegel R, Cangianelli L, Baudys J, Atkins R (2005) An evaluation of selected oral fluid point-of-collection drug-testing devices. J Anal Toxicol 29(4): 244-248, Epub 2005/06/25.
89. White ID, Hoskin PJ, Hanks GW, Bliss JM (1989) Morphine and dryness of the mouth. BMJ 298(6682): 1222-1223, Epub 1989/05/06.
90. Moore C, Feldman M, Harrison E, Rana S, Coulter C, Kuntz D et al (2006) Disposition of hydrocodone in hair. J Anal Toxicol 30(6): 353-359, Epub 2006/07/29.
91. Kintz P, Brenneisen R, Bundeli P, Mangin P (1997) Sweat testing for heroin and metabolites in a heroin maintenance program. Clin Chem Epub 1997/05/01(5): 736-739, Epub 1997/05/01.
92. Chawarski MC, Fiellin DA, O'Connor PG, Bernard M, Schottenfeld RS (2007) Utility of sweat patch testing for drug use monitoring in outpatient treatment for opiate dependence. J Subst Abus Treat 33(4): 411-415, Epub 2007/05/22.
93. Huestis MA, Cone EJ, Wong CJ, Umbricht A, Preston KL (2000) Monitoring opiate use in substance abuse treatment patients with sweat and urine drug testing. J Anal Toxicol 24(7): 509-521, Epub 2000/10/24.
94. Schwilke EW, Barnes AJ, Kacinko SL, Cone EJ, Moolchan ET, Huestis MA (2006) Opioid disposition in human sweat after controlled oral codeine administration. Clin Chem 52(8): 1539-1545, Epub 2006/06/03.
95. Haller DL, Acosta MC, Lewis D, Miles DR, Schiano T, Shapiro PA et al (2010) Hair analysis versus conventional methods of drug testing in substance abusers seeking organ transplantation. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg 10(5): 1305-1311, Epub 2010/04/01.
96. Musshoff F, Driever F, Lachenmeier K, Lachenmeier DW, Banger M, Madea B (2006) Results of hair analyses for drugs of abuse and comparison with selfreports and urine tests. Forensic Sci Int 156(2-3): 118-123, Epub 2006/01/18.
97. Romano G, Barbera N, Lombardo I (2001) Hair testing for drugs of abuse: evaluation of external cocaine contamination and risk of false positives. Forensic Sci Int 123(2-3): 119-129, Epub 2001/12/01.
98. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS (1999) Validity of selfreported drug use in chronic pain patients. Clin J Pain 15(3): 184-91.
99. Cone EJ, Caplan YH (2009) Urine toxicology testing in chronic pain management. Postgrad Med 121(4): 91-102, Epub 2009/07/31.